June 2, 2016
(STAT News) – A pioneering California company that’s spent tens of millions and nearly three decades trying to develop therapies using stem cells is shutting down after failing to move treatments through clinical trials — but advocates of stem cell treatments say they’re convinced the approach still holds great promise. StemCells Inc., based in Newark, Calif., has long been seen as a leader in regenerative medicine. The field aims to use highly flexible stem cells — which have the potential to develop into heart, muscle, brain, or any other type of cell — to heal damaged tissues and organs.
The views, opinions and positions expressed by these authors and blogs are theirs and do not necessarily represent that of the Bioethics Research Library and Kennedy Institute of Ethics or Georgetown University.